尊龙凯时,尊龙凯时医药集团股份公司官网,尊龙凯时医药集团股份公司,尊龙凯时甾体激素,尊龙凯时麻醉药品

Technology Platform
OVERVIEW
01

R&D Directions

02

R&D Projects

03

Intellectual Property

04

Innovative Platform

05

Innovative Talents

The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.

More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.

The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.

The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, China.

The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.

While building a first-class platform for R&D and innovation, the company provides all-around service from research, development, and clinical trials to registration of new drugs.

The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.

Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and 7 experts enjoying a special allowance of The State Council.

The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.
More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.
The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, Chi
The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.While building a first-class platform for R&D and innovation, the
The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and

Development Progress

R&D Centers

Technology Platform
Technology platform for innovative small molecule drugs

Design of novel molecules that are non-addictive and non-respiratory depressant.

Technology platform for long-acting microspheres and liposomes

Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.

Technology platform for transdermal administration

Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.

Technology platform for anti-abuse design of special drugs

Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.

Technology platform for oral sustained-release and controlled -release drugs

To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.

Technology platform for oral mucous administration

Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.

Technology Platform
Technology platform for innovative small molecule drugs

Design of novel molecules that are non-addictive and non-respiratory depressant.

Technology platform for long-acting microspheres and liposomes

Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.

Technology platform for transdermal administration

Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.

Technology platform for anti-abuse design of special drugs

Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.

Technology platform for oral sustained-release and controlled -release drugs

To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.

Technology platform for oral mucous administration

Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.